Cargando…

Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment

BACKGROUND: Both statins and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors lower blood low-density lipoprotein cholesterol levels to reduce risk of cardiovascular events. To assess potential differences between metabolic effects of these 2 lipid-lowering therapies, we performed de...

Descripción completa

Detalles Bibliográficos
Autores principales: Sliz, Eeva, Kettunen, Johannes, Holmes, Michael V., Williams, Clare Oliver, Boachie, Charles, Wang, Qin, Männikkö, Minna, Sebert, Sylvain, Walters, Robin, Lin, Kuang, Millwood, Iona Y., Clarke, Robert, Li, Liming, Rankin, Naomi, Welsh, Paul, Delles, Christian, Jukema, J. Wouter, Trompet, Stella, Ford, Ian, Perola, Markus, Salomaa, Veikko, Järvelin, Marjo-Riitta, Chen, Zhengming, Lawlor, Debbie A., Ala-Korpela, Mika, Danesh, John, Davey Smith, George, Sattar, Naveed, Butterworth, Adam, Würtz, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254781/
https://www.ncbi.nlm.nih.gov/pubmed/30524137
http://dx.doi.org/10.1161/CIRCULATIONAHA.118.034942

Ejemplares similares